Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
But that decision didnt take effect until 2026, so the outlays on the drugs continued to weigh on the financials throughout 2025
In the same trial, 1-8% of patients reported injection site reactions with retatrutide, while no case was reported in the placebo group
You should avoid drinking too much at a single time
This raises the question of whether other payers will stop coverage and follow suit
Type 2 Diabetes: TRANSCEND-T2D-1 In March 2026, Eli Lilly published topline results from TRANSCEND-T2D-1 the Phase 3 trial of retatrutide in adults with type 2 diabetes
Octavio Rojas Diaz 5555368017 5555430755 5517038557
